Urolog. pro Praxi, 2005; 3: 110-117

ADVANCED CARCINOMA OF PROSTATE - OVERVIEW OF THERAPEUTIC OPTIONS

MUDr. Ivan Kolombo FEBU
Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha

Carcinoma of the prostate is the most frequent malignant tumour in men. Significant number of patients is primarily diagnosed with advanced disease or progress during the follow-up. New treatment regimens are being developed, which substantially decrease the risk of progression or effectively decrease the incidence of complications. These are bicalutamide and zoledronate in the first place. The article gives an overview and summary of recent opinions on the treatment of advanced carcinoma of prostate.

Keywords: Key words: carcinoma of prostate, treatment, bicalutamide, zoledronate.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolombo I. ADVANCED CARCINOMA OF PROSTATE - OVERVIEW OF THERAPEUTIC OPTIONS. Urol. praxi. 2005;6(3):110-117.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahamsson PA. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol 2003; (Suppl): 1-2. Go to original source...
    2. Aus G, Abbou CC, Heidenreich A, Schmidt HP, van Poppel H, Wolff JM, Zattoni F. EAU Guidelines on prostate cancer, Update February 2003.
    3. Babjuk M, Matoušková M, Novák J. Zhoubné nádory prostaty; 17-27, In Doporučené diagnostické a léčebné postupy u urologických nádorů, Galén, 2003.
    4. Bartsh G, Chi K, Cussenot O, Frenkel E, Gleave M, Klocker H, Logothetis C, Miyake H, Schalken J. Innovative Approachs in Medical Management of Prostate Cancer: Other than Hormonal Therapies. In Prostate Cancer-3rd International Consultation on Prostate Cancer-Paris Edit Denis L, Bartsh G, Khoury S, Kurzi M, Partin A, Paris Health Publications 2003; 159-216.
    5. Basaria S. Long-term effect of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56,6: 779-786. Go to original source... Go to PubMed...
    6. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulátor proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-1516. Go to original source...
    7. Belej K, Záťura F, Belejová M. Hormonální léčba adenokarcinomu prostaty. Praha, StudiaGeo, 2004, 147-159.
    8. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates. J Urol 2001; 166: 2023-2031. Go to original source... Go to PubMed...
    9. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-1107. Go to original source... Go to PubMed...
    10. Bok RA, Small EJ. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf 1999; 20: 451-458. Go to original source... Go to PubMed...
    11. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166. Go to original source... Go to PubMed...
    12. Breza J, Bolješíková E, Kliment J. Liečba lokalizovaného karcinómu prostaty In Kliment J, Horňák M. Karcinóm prostaty, Martin Osveta, 1999, 159-193.
    13. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, a kol. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057-1064. Go to original source... Go to PubMed...
    14. Bubendorf L, Schopfer A, Wagner U, Kauter G, Moch H, Wili N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583. Go to original source... Go to PubMed...
    15. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Co-operative Urological Research Group studies. NCI Monogr 1988; 165-170.
    16. Byar DP. Proceedings: The Veterans Administration Co-operative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-1130. Go to original source...
    17. Campa III JA, Payne R. The management of intractable bone pain: a clinician´s perspektive. Semin Nucl Med 1992; 22: 3-10. Go to original source... Go to PubMed...
    18. Cancer incidence in Sweden 2000. The national board of health and welfare.
    19. Carducci MA, Nelson JB, Humerickhouse R, Weinberg M, Schmitt J, Nabulsi A. Effects of atrasentan on progression and survival in men with hormone-refractory prostate cancer: follow-up to study M96-594. J Clin Oncol 2002; (Suppl): Abstract 708.
    20. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW. Phenylbutyrate induced apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379-387.
    21. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, a kol. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomised, phase II, placebo-controlled trial. J Clin Oncol 2003; 21(4): 679-689. Go to original source... Go to PubMed...
    22. Carroll PR, Altwein J, Brawley A, Cockett M, Cooperberg Y, Hirao B, Lobel D, McLeod D, Neal D, Van Poppel H, Richard F, Scher H, Wood C. Management of Disseminated Prostate Cancer In Prostate Cancer-3rd International Consultation on Prostate Cancer-Paris Edit Denis L, Bartsh G, Khoury S, Kurzi M, Partin A, Paris Health Publications 2003; 249-284.
    23. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1004. Go to original source... Go to PubMed...
    24. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology, 2001; 58 (Suppl 2A): 101-107. Go to original source... Go to PubMed...
    25. Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174-184.
    26. de Reijke TM, Derobert E. International Anandron Study Group: Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus Anandron or placebo: a final update. Eur Urol 2002; 42: 139-146. Go to original source... Go to PubMed...
    27. Debruyne FMJ, Akaza H, Spermon JR, Klotz L,Chopin D, Di Silverio F, Calais da Silva F, Habib F, Mahler C. Innovative Approaches in Medical Management of Prostate Cancer: Hormones. In Prostate Cancer-3rd International Consultation on Prostate Cancer-Paris Edit Denis L, Bartsh G, Khoury S, Kurzi M, Partin A, Paris Health Publications 2003; 139-158.
    28. Desai A, Stadler WM, Vogelzang N. Nilutamide: possible utility as a second-line hormonal agent. Urology 2000; 58: 1016-1020. Go to original source... Go to PubMed...
    29. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate cancer. Cancer, 1998; 83: 1561-1566. Go to original source...
    30. Dickie GJ, Macfarlane D. Stroncium and samarium therapy for bone metastases from prostate carcinoma. Australan Radiol 1999; 43: 476-479. Go to original source... Go to PubMed...
    31. Dušek P, Jarolím L, Kawaciuk I, Hyršl L. Chemoterapie hormonálně independentního karcinomu prostaty; 47-48, In Abrahámová J: Vybrané otázky onkologie VII., Praha Galén, 2003.
    32. Dvořáček J. Aktuální aspekty léčby karcinomu prostaty In Kurz IPVZ Aktuální aspekty léčby urologických onemocnění - přednáška 29. 11. 2003, Katedra IPVZ Praha.
    33. Elomaa I, Kylmälä T, Tammela T, Viitanen J, Otrelin J, Ruutu M a kol: Effect of oral clodronate on bone pain. A controlled study in patiens with metastatic prostatic cancer. Int Urol Nephrol 1992; 24: 159-166. Go to original source... Go to PubMed...
    34. Ferlay J, Bray F, Pisani P, Parken DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. Limited version available at: http://www-dep.iarc.fr/globocan/globocan.html. In IARC CancerBase No. 5. Lyon: IARC Press; 2001.
    35. Ferro MA, Gilliatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1998; 52: 252-256. Go to PubMed...
    36. Fiala R, Záťura F, Ženíšek J. Adenokarcinom prostaty od PSA k terapii. Edice Urolog, č.1/2001, StudiaGeo, Praha.
    37. Foss' SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2001; 19: 62-71. Go to original source... Go to PubMed...
    38. Fowler JE, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deffered flutamide treatment. J Urol 1995; 154: 448-453. Go to original source... Go to PubMed...
    39. Fowler JE, Whitmore WF. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982; 49: 1373-1377. Go to original source... Go to PubMed...
    40. Fowler JE, Whitmore WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-375. Go to original source... Go to PubMed...
    41. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33. Go to original source... Go to PubMed...
    42. Groot MT, Boeken Kruger CGG, Pelger RCM, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. European Urology 2003; 43: 226-232. Go to original source... Go to PubMed...
    43. Hamdy FC. Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer. Eur Urol 2003; Suppl 2: 15-19. Go to original source...
    44. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017. Go to original source... Go to PubMed...
    45. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001; 61: 2177-2192. Go to original source... Go to PubMed...
    46. Hart SM. Modulatio of nuclear receptor dependent transcription. Biol Res 2002; 35: 295-303. Go to original source... Go to PubMed...
    47. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int., 2000; 86: 449-452. Go to original source... Go to PubMed...
    48. Havranek EG, Whelan MA, Greenhalgh R, et al. Advances in prostate cancer immunotherapy. Surg Oncol 2002; 11: 35-45. Go to original source... Go to PubMed...
    49. Hedlund PO, Henriksen P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000; 55: 328-333. Go to original source... Go to PubMed...
    50. Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
    51. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advenced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690-694. Go to original source... Go to PubMed...
    52. Cheng EY: Prospective quality of life research in bony metastatic disease. Clin Orthop 2003; (suppl): 289-297. Go to original source... Go to PubMed...
    53. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patiens with metastatic prostate cancer: DAPROCA study 9002. J Urol 1997; 157: 929-934. Go to original source... Go to PubMed...
    54. Iversen P. Course 30 - Advenced course on prostate cancer -new perspectives. Endocrine therapy - timing and modalities. ESU Courses, Birmingham, United Kingdom, Tuesday, February 26: 2002.
    55. Iversen P. Current Topics in the Treatment of Hormone-refractory Prostate Cancer. Eur Urol Suppl 2003; 2: 3-8. Go to original source...
    56. Jager PL, Kooistra A, Piers DA. Treatment with radioactive (89) stroncium for patients with bone metastases from prostate cancer. BJU Int 2000; 86: 929-934. Go to original source... Go to PubMed...
    57. Jarolím J, Matoušková M. Kostní komplikace u pokročilého karcinomu prostaty. In: Zometa v prevenci kostních komplikací - přednáška Seminář 28. 1. 2004, Praha.
    58. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003; 53: 5-26. Go to original source... Go to PubMed...
    59. Kelly WK Scher HI. Prostate specific antigen cecline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607-609. Go to original source... Go to PubMed...
    60. Kelly WK, Curley T, Slovin S, Keller G, McCaffrey J, Bajorin D, et al. Paclitaxel, estramustin phosphate and carboplatin in patiens with advenced prostate cancer. J Clin Oncol 2001; 19: 44-53. Go to original source... Go to PubMed...
    61. Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998; 34: 18-23. Go to original source... Go to PubMed...
    62. Kim IY, Ahn HJ, Kelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. Los sof expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2: 1255-1261.
    63. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001; 8: 487-495. Go to original source... Go to PubMed...
    64. Kliment J. Paliatívna liečba karcinómu prostaty In Kliment J, Horňák M Karcinóm prostaty, Martin Osveta, 1999, 291-297.
    65. Kolombo I, Kolombová J, Bernat D, Hrubý M, Porš J, et al. Skeletální postižení při karcinomu prostaty představuje komplexní problém - kazuistická sdělení ve světle nových poznatků. Česká urologie 2004; 1: 29-33.
    66. Kolombo I, Kolombová J, Berndt D, Hrubý M, Porš J, Fröml J, a kol. Skeletální postižení při karcinomu prostaty představuje komplexní problém; 52-55, In Abrahámová J: Vybrané otázky onkologie VII., Galén Praha, 2003, 54-57.
    67. Kylmälä T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I. Concomitant i.v. and oral clodronate in the reliéf of bone pain - a double-blind placebo-controlled study in patiens with prostate cancer. Br J Cancer 1997; 76: 939-942. Go to original source... Go to PubMed...
    68. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-18. Go to original source... Go to PubMed...
    69. Landstrom M, Damber JE, Bergh A. Estrogen treatment postpones the castration-induced dedifferentation of Dubbing R3327-PAP prostatic adenocarcinoma. Prostate 1994; 25: 10-18. Go to original source... Go to PubMed...
    70. Lenz HJ. Why pharmacogenomics and molecular biology are the future of oncology 2-7, In Improving the efficacy of standard therapy in solid tumors: State of the art today and tomorrow. Industrial satelite symposium 2002; Salle Athena, Nice Akropolis.
    71. MacGrogan D, Bookstein R. Tumor suppressor genes in prostate cancer. Semin Cancer Biol 1997; 8: 11-19. Go to original source... Go to PubMed...
    72. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metasteses and selection of clinical endpoints. Am J Clin Oncol 2002; 25 (6 Suppl 1): S10-18. Go to original source... Go to PubMed...
    73. Matoušková M, Hanuš M. Intermitentní androgenní suprese (IAS) v léčbě karcinomu prostaty. Česká urologie 2003; 2: 11-15.
    74. Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-246. Go to original source... Go to PubMed...
    75. Newling D, Fossa SD,Anderson L, Abrahamsson P-A, Aso Y, Eisenberger MA, et al. Assessment of hormone refraktory prostate cancer. Urology 1997; 49: 46-53. Go to original source... Go to PubMed...
    76. Odrážka K, Vaculíková M, Zouhar M, Petera J, Vošmik M, Doležel M, Prošvic P. Chronická toxicita konformní radioterapie karcinomu prostaty; 42-45, In Abrahámová J: Vybrané otázky onkologie VII., Praha Galén, 2003.
    77. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-1007. Go to original source...
    78. Oefelein MG, Ricchuiti V, Conrad W, Seftel A,Bodner D, Goldman W, a kol. Skeletal fracture associated with androgen supression induced osteoporosis: the clinical incidence and risk factors for patiens with prostate cancer. J Urol 2001; 166: 1724-1728. Go to original source... Go to PubMed...
    79. Oh WK. Chemotherapy for patients with advenced prostate carcinoma: a new option for therapy. Cancer 2000; 88: 3015-3021. Go to original source...
    80. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology (Huntingt) 1999; 13: 1537-1549.
    81. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology (Huntingt) 1999; 13: 1537-1549.
    82. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Grahem J, Adami S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604. Go to original source... Go to PubMed...
    83. Pacík D. Aktuální informace o karcinomu prostaty. Urologické listy 2003; 1: 7-12.
    84. Paul R, Breaul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 2000; 23: 381-390. Go to original source... Go to PubMed...
    85. Povýšil C, Šafařík L, Vachalovský V. Nádory prostaty, 1035-1140, In Dvořáček J, Urologie, Praha, ISV, 1998: II. díl.
    86. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-269. Go to original source...
    87. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498. Go to original source...
    88. Saad F, Gleason DM, Murray R, a kol. Zoledronic acid significantly reduced the bone pain in patients with advanced prostate cancer metastatic to bone (abstract). Presented at: 3rd North American Symposium: Skeletal complications of malignancy; April 25-27, 2002; Bethesda, Maryland.
    89. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma. Jour of the National Cancer Institute 2002; 94: 1458-1468. Go to original source... Go to PubMed...
    90. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J, Vinholes J, Goas JA, Chen BL, Seman J. Zoledronic acid is well tolerated for up to 24 months and singnificantly reduces skeletal comlplications in patiens with advanced prostate cancer metastatic to bone. American Urological Association Annual Meeting 2003 (poster).
    91. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45: 26-34. Go to original source... Go to PubMed...
    92. Saad F. Recent advances in the treatment of metastatic prostate cancer. Genitourinary cancer: management of skeletal complications. An official EAU satellite symposium of XIXth congress of the European Association of Urology Vienna 2004; Abstract 24 March 2004: 10-11.
    93. Sessions AE. Timing hormonal therapy in prostate cancer. Urol Clin North Am 2002; 29: 223-227. Go to original source... Go to PubMed...
    94. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Maculoso M, Mattealaer J, van Velthoven RF, Debois M, Collette L. Metastatic prostate cancer treated by flutamide versus cyproterone acetáte. Final analysisi of the, ,European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 2004; 45: 457-464. Go to original source... Go to PubMed...
    95. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains aktivity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-1207. Go to original source... Go to PubMed...
    96. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-3903. Go to original source... Go to PubMed...
    97. Smith DC, Redman BG, Flaherty LE, Li L, Stawderman M, Pienta KJ. A phase II trial of oral diethylstilbestrol as a sekond-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257-260. Go to original source... Go to PubMed...
    98. Smith DC. Secondary hormonal therapy. Semin Urol Oncol 1997; 15: 3-12.
    99. Smith MR, Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003; 20: 175-183. Go to original source... Go to PubMed...
    100. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003; 20: 175-183. Go to original source... Go to PubMed...
    101. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012. Go to original source... Go to PubMed...
    102. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012. Go to original source... Go to PubMed...
    103. Smith MR, Kantoff PW. Peroxisome proliferation-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Incest New Drugs 2002; 20: 195-200. Go to original source... Go to PubMed...
    104. Smith MR, Kantoff PW. Peroxisome proliferation-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Incest New Drugs 2002; 20: 195-200. Go to original source... Go to PubMed...
    105. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA a kol. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955. Go to original source... Go to PubMed...
    106. Smith MR, Shasha D, Mansour R, Zinner N. Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at: 3rd North American Symposium: Skeletal complications of malignancy; April 25-27, 2002; Bethesda, Maryland.
    107. Smith MR. Role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy; 14-18. In Evolving role of bisphosphonates for cancer treatment-induced bone loss. Profesional excelence in medical education, 2003.
    108. Sommers SD, Ramsey SD. A review of quality-of-life evalutions in prostate cancer. Pharmacoeconomics 1999; 16: 127-140. Go to original source... Go to PubMed...
    109. Stapleton AM, Timme TL, Gausse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Sardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997; 3: 1389-1397.
    110. Sternberg CN. Cuurent Perspective: What´s new in the treatment of advanced prostate cancer? Eur J Can 2003; 39: 136-146. Go to original source... Go to PubMed...
    111. Tannock IF, Osoba D, Stockler MR, Ernst DS, Seville AJ, Moore MJ, Armitage GR, Wilson JJ, Verner PM, Coppin CM, Murphny KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randmized trial with paliative end points. J Clin Oncol 1996; 14: 1756-1764. Go to original source... Go to PubMed...
    112. Taplin ME, Bublej GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398. Go to original source... Go to PubMed...
    113. van der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004; 45: 1-17. Go to original source... Go to PubMed...
    114. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen supression in prostate cancer - evidence for deferred treatment. J Urol 2001; 166(2): 508-515. Go to original source... Go to PubMed...
    115. Walsh PC. Immediate versus deffered treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997; 158: 1623-1624. Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.